Abstract
Adenocarcinoma of the prostate is currently the most common malignancy and second leading cause of death from cancer in men in the United States (Wingo et al. 1995). It has been estimated that 244 000 new cases of prostate cancer will be diagnosed in the United States in 1995, resulting in 40 400 prostate cancer deaths during the same period (Wingo et al. 1995). This estimate represents a 100% increase in new cases of prostate cancer when compared with 1991 (Boring et al. 1991). The discovery and subsequent routine use of serum prostate-specific antigen (PSA) is the most important factor leading to this dramatic increase in prostate cancer detection. While controversy still exists in the literature regarding the benefits of routine screening for prostate cancer, it is becoming standard practice amongst physicians to screen men over 50 years of age for prostate cancer on a yearly basis using both digital rectal examination (DRE) and serum PSA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
